How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?

In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.

As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.

Key clinical takeaways:

• Pair the right patient with the right treatment using an understanding of the key clinical studies

• The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data

• The best outcomes are achieved through multi-disciplinary collaborations that include the patient

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true

X: https://x.com/net_connectinfo

This content is intended for healthcare professionals only.

This podcast is supported by an Independent Education Grant from ITM.

This podcast is developed by cor2ed.com

Published September 2025

Hear from Dr Andrew Dauber and Dr Marta Ramón Krauel in this podcast as they explore short stature conditions, including SPIGFD (severe primary IGF-1 deficiency) / growth hormone resistance, through real patient cases and clinical insights. While growth hormone deficiency is a well-known cause of short stature, this discussion covers patient cases where growth hormone levels are normal or even elevated, yet IGF-1 levels remain low—a hallmark of primary IGF-1 deficiency.

Gain valuable knowledge on identifying and managing this rare condition, with practical takeaways for clinical practice.

Key clinical takeaways:

• Growth hormone resistance can range from severe IGF-1 deficiency, like in classic Laron syndrome, to milder mutations in the same receptor. There can also be mutations in other parts of the signalling pathway

• Patients with SPIGFD have low IGF-1 levels resulting from growth hormone resistance or insensitivity, rather than deficiency, as they produce sufficient or even high levels of growth hormone without secondary causes of growth failure

• Laron syndrome, a classic form of SPIGFD, is characterised by severe short stature and distinct features such as spontaneous hypoglycemia, mid-face hypoplasia, frontal bossing, a high-pitched voice, and underdeveloped genitalia in boys

• Early and accurate diagnosis of SPIGFD is crucial for effective management, as growth hormone therapy is ineffective for these patients; recognising the distinction between severe and less severe IGF-1 deficiency, as well as primary versus secondary causes, ensures appropriate treatment to ensure optimal outcomes

• Recombinant IGF-1 therapy is indicated for patients with SPIGFD. Healthcare professionals must monitor for adverse events such as hypoglycemia and potential malignancies

Follow us on social media:

LinkedIn: https://www.linkedin.com/showcase/pe-connect/

X: https://x.com/peconnectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Ipsen

This podcast is developed by cor2ed.com

Published December 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.